Holen Sie sich die Stockscreener-App
0.83
4.71%
-0.041
Handel nachbörslich:
.86
0.03
+3.61%
Schlusskurs vom Vortag:
$0.871
Offen:
$0.88
24-Stunden-Volumen:
954.28K
Relative Volume:
1.55
Marktkapitalisierung:
$33.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.58M
KGV:
-0.3132
EPS:
-2.65
Netto-Cashflow:
$-42.82M
1W Leistung:
-15.31%
1M Leistung:
-16.16%
6M Leistung:
-45.39%
1J Leistung:
-33.60%
1-Tages-Spanne:
$0.814
$0.894
1-Wochen-Bereich:
$0.814
$0.9997
52-Wochen-Spanne:
$0.808
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Firmenname
Iterum Therapeutics Plc
Sektor
Branche
Telefon
(872) 225-6077
Adresse
3 DUBLIN LANDINGS, DUBLIN 1
Vergleichen Sie ITRM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.83 | 39.20M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2021-03-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | Herabstufung | Gabelli & Co | Buy → Sell |
| 2019-12-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Iterum Therapeutics Plc Aktie (ITRM) Neueste Nachrichten
Is Iterum Therapeutics plc a good long term investmentFree Predictions - jammulinksnews.com
What drives Iterum Therapeutics plc stock priceTriple returns potential - jammulinksnews.com
Iterum Therapeutics plc Stock Analysis and ForecastOutstanding growth strategies - jammulinksnews.com
What analysts say about Iterum Therapeutics plc stockHigh-profit capital plays - jammulinksnews.com
Why Iterum Therapeutics plc stock attracts strong analyst attentionMassive Profit Potential - Newser
What makes Iterum Therapeutics plc stock price move sharplyWatchlist Winner Update - Newser
How Iterum Therapeutics plc stock performs during market volatilityFree Access to Investment Community - Newser
OneDigital Investment Advisors LLC Invests $124,000 in Iterum Therapeutics PLC (NASDAQ:ITRM) - Defense World
Iterum Therapeutics (NASDAQ:ITRM) Trading Down 4.2% – Here’s What Happened - Defense World
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Iterum Strengthens Launch Strategy: 30-Year Pharma Veteran Christine Coyne to Lead ORLYNVAH Commercialization - Stock Titan
Iterum Names Christine Coyne as Chief Commercial Officer to Lead - GuruFocus
Certain Options of Iterum Therapeutics plc are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Certain Ordinary Shares of Iterum Therapeutics plc are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Iterum Therapeutics (ITRM) Releases Positive Phase 3 Trial Resul - GuruFocus
Iterum Therapeutics (ITRM) Releases Positive Phase 3 Trial Results | ITRM Stock News - GuruFocus
New Antibiotic Shows Promise Against Drug-Resistant UTIs: NEJM Evidence Reveals 9.2% Multi-Resistance Rate - Stock Titan
Transcript : Iterum Therapeutics plcSpecial Call - MarketScreener
Research Analysts Set Expectations for ITRM FY2026 Earnings - Defense World
Two Sigma Investments LP Invests $45,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
EVERSANA expands commercialisation portfolio with OS Therapies and Iterum Therapeutics partnerships - pharmaphorum
Citadel Advisors LLC Acquires Shares of 21,207 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics (ITRM) Partners with EVERSANA for U.S. Launc - GuruFocus
Iterum Therapeutics announces partnership with EVERSANA - PharmaLive
Iterum Therapeutics inks deal for ORLYNVAH commercialization By Investing.com - Investing.com Nigeria
Iterum Therapeutics inks deal for ORLYNVAH commercialization - Investing.com
Iterum Therapeutics Announces Partnership for Commercialization Services - Yahoo Finance
Breakthrough UTI Drug ORLYNVAH Set for Q4 2025 Launch: First Oral Penem Antibiotic in US History - Stock Titan
Pfizer grants Iterum payment extension for FDA-approved antibiotic By Investing.com - Investing.com South Africa
Pfizer grants Iterum payment extension for FDA-approved antibiotic - Investing.com Australia
Iterum Therapeutics Announces Extension of Term of Promissory No - GuruFocus
Iterum Therapeutics (ITRM) Extends $20M Payment Deadline with Pf - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory Note | ITRM Stock News - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory Note - The Manila Times
Iterum Therapeutics Announces Extension of $20 Million Regulatory Milestone Payment Deadline with Pfizer to 2029 - Nasdaq
Iterum Gains 3-Year Extension on $20M Pfizer Payment, Strengthens ORLYNVAH Launch Strategy - Stock Titan
Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026 - MSN
Finanzdaten der Iterum Therapeutics Plc-Aktie (ITRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):